New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
07:33 EDTDSCIDerma Sciences reports Q4 EPS (31c), consensus (36c)
Reports Q4 revenue $20.7M, consensus $21.26M. The company said, "The increase in net loss was principally due to higher growth related selling, general and administrative expenses including higher stock-based compensation and legal expenses and taxes."
News For DSCI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 26, 2015
10:00 EDTDSCIOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:48 EDTDSCIDerma Sciences downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray downgraded Derma Sciences to Neutral citing a lack of growth catalysts with management's "tepid" expectations regarding the growth of the advanced wound care segment in 2015. Piper cut its price target for shares to $9 from $12.
January 22, 2015
09:18 EDTDSCIDerma Sciences' amniotic tissue products incorporated to Premier portfolio
Derma Sciences' (DSCI) Amnioexcel and Amniomatrix , amniotic allografts derived from placental tissues, have been added to the Premier (PINC) Regenerative Skin Grafting contract portfolio.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use